These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 30637500)
1. Diagnostic manifestations of total hemispheric glucose metabolism ratio in neuronal network diaschisis: diagnostic implications in Alzheimer's disease and mild cognitive impairment. Segtnan EA; Majdi A; Constantinescu C; Grupe P; Gerke O; Dali HÍ; Strøm OE; Holm J; Alavi A; Sadigh-Eteghad S; Wermuth L; Hildebrandt MG; Gjedde A; Høilund-Carlsen PF Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1164-1174. PubMed ID: 30637500 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Implications of Total Hemispheric Glucose Metabolism Ratio in Cerebrocerebellar Diaschisis. Segtnan EA; Grupe P; Jarden JO; Gerke O; Ivanidze J; Christlieb SB; Constantinescu C; Pedersen JE; Houshmand S; Hess S; Zarei M; Gjedde A; Alavi A; Høilund-Carlsen PF J Nucl Med; 2017 May; 58(5):768-773. PubMed ID: 27789719 [TBL] [Abstract][Full Text] [Related]
3. Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism. Smailovic U; Koenig T; Savitcheva I; Chiotis K; Nordberg A; Blennow K; Winblad B; Jelic V Brain Connect; 2020 Dec; 10(10):555-565. PubMed ID: 33073602 [No Abstract] [Full Text] [Related]
4. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion. Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523 [TBL] [Abstract][Full Text] [Related]
5. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease. Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938 [TBL] [Abstract][Full Text] [Related]
6. Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment. Weise CM; Chen K; Chen Y; Kuang X; Savage CR; Reiman EM; Neuroimage Clin; 2018; 20():286-296. PubMed ID: 30101060 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous resting-state FDG-PET/fMRI in Alzheimer Disease: Relationship between glucose metabolism and intrinsic activity. Marchitelli R; Aiello M; Cachia A; Quarantelli M; Cavaliere C; Postiglione A; Tedeschi G; Montella P; Milan G; Salvatore M; Salvatore E; Baron JC; Pappatà S Neuroimage; 2018 Aug; 176():246-258. PubMed ID: 29709628 [TBL] [Abstract][Full Text] [Related]
8. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment. Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056 [TBL] [Abstract][Full Text] [Related]
9. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study. Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S; J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728 [TBL] [Abstract][Full Text] [Related]
10. Apathy as a feature of prodromal Alzheimer's disease: an FDG-PET ADNI study. Delrieu J; Desmidt T; Camus V; Sourdet S; Boutoleau-Bretonnière C; Mullin E; Vellas B; Payoux P; Lebouvier T; Int J Geriatr Psychiatry; 2015 May; 30(5):470-7. PubMed ID: 24953008 [TBL] [Abstract][Full Text] [Related]
11. Aberrant Connectivity in Mild Cognitive Impairment and Alzheimer Disease Revealed by Multimodal Neuroimaging Data. Li Q; Wu X; Xie F; Chen K; Yao L; Zhang J; Guo X; Li R; Neurodegener Dis; 2018; 18(1):5-18. PubMed ID: 29334684 [TBL] [Abstract][Full Text] [Related]
12. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism. Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A; J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655 [TBL] [Abstract][Full Text] [Related]
13. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821 [TBL] [Abstract][Full Text] [Related]
14. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI. Ben Bouallègue F; Mariano-Goulart D; Payoux P; J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345 [TBL] [Abstract][Full Text] [Related]
15. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population. Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632 [TBL] [Abstract][Full Text] [Related]
16. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117 [TBL] [Abstract][Full Text] [Related]
17. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment. Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417 [TBL] [Abstract][Full Text] [Related]
18. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum. Tosun D; Schuff N; Jagust W; Weiner MW; Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336 [TBL] [Abstract][Full Text] [Related]